Battle Against Cancer trust backs Woodford's Patient Capital

Alice Rigby
clock

The Battle Against Cancer investment trust (BACIT) has backed Woodford's Patient Capital trust at launch.

In its half yearly update to investors, BACIT announced that it had bought into the Patient Capital trust during its IPO period earlier this month. The trust's management said it was attracted to Woodford's company, which invests in early-stage companies, as it offers "growth at a reasonable price". BACIT also introduced two global macro funds, the Parity Value fund and Seia Global Macro fund, to its portfolio during the period. The Patient Capital trust IPO was the largest UK-listed trust launch in history, raising £800m after initially capping fundraising at £500m. BACIT is a ...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Investment Trusts

Although the sector closed the year in positive territory, investment trust performance was 'well behind' US and global equity market indices.

Investment trusts close 2023 with 4.6% performance boost

Numis research

Cristian Angeloni
clock 03 January 2024 • 3 min read
Charlotte Cuthbertson (pictured), fund manager at Asset Value Investors and co-manager of MIGO Opportunities trust

AVI's Charlotte Cuthbertson: The resilient reinvention of investment trusts

Autumn of 2023 'golden period' for ITs

Charlotte Cuthbertson
clock 21 December 2023 • 5 min read
The total debt for the company stood at $674m as of 31 September, which represented 32.0% of operative NAV.

Hipgnosis narrowly avoids share suspension with publication of interim results

Continued tension with investment adviser

Eve Maddock-Jones
clock 21 December 2023 • 3 min read
Trustpilot